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Abstract
Background: Cryptococcal meningitis (CM) remains a leading cause of death for HIV-infected individuals in sub-Saharan
Africa. Improved treatment strategies are needed if individuals are to benefit from the increasing availability of antiretroviral
therapy. We investigated the factors associated with mortality in routine care in KwaZulu-Natal, South Africa.
Methodology/Principal Findings: A prospective year long, single-center, consecutive case series of individuals diagnosed
with cryptococcal meningitis 190 patients were diagnosed with culture positive cryptococcal meningitis, of whom 186 were
included in the study. 52/186 (28.0%) patients died within 14 days of diagnosis and 60/186 (32.3%) had died by day 28. In
multivariable cox regression analysis, focal neurology (aHR 11 95%C.I. 3.08–39.3, P,0.001), diastolic blood pressure
,60 mmHg (aHR 2.37 95%C.I. 1.11–5.04, P=0.025), concurrent treatment for tuberculosis (aHR 2.11 95%C.I. 1.02–4.35,
P=0.044) and use of fluconazole monotherapy (aHR 3.69 95% C.I. 1.74–7.85, P,0.001) were associated with increased
mortality at 14 and 28 days.
Conclusions: Even in a setting where amphotericin B is available, mortality from cryptococcal meningitis in this setting is
high, particularly in the immediate period after diagnosis. This highlights the still unmet need not only for earlier diagnosis
of HIV and timely access to treatment of opportunistic infections, but for better treatment strategies of cryptococcal
meningitis.
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Introduction
Despite the increasingly widespread availability of highly active
antiretroviral therapy (HAART) throughout sub-Saharan Africa,
HIV remains the leading cause of death amongst adults in many
populations, particularly in rural Southern Africa [1] Prior to the
availability of antiretrovirals, cryptococcal meningitis (CM)
accounted for a significant proportion of deaths in HIV infected
individuals [2–4] and even with increasing availability of HAART,
recent data suggests that CM may account for more deaths
amongst HIV positive individuals in sub-Saharan Africa than
tuberculosis [5].
For many individuals with HIV, their first presentation to health
services is with a major opportunistic infection such as CM and
optimal management in these individuals is crucial if they are to
benefit fully from antiretroviral therapy. Data from different
healthcare settings is valuable for the identification of factors
associated with treatment outcome and understanding which
interventions are necessary to improve survival. The clinical
diagnosis and management of CM differ between clinical settings
depending on resources available [6]. Availability of diagnostics,
drugs and trained nursing and medical staff, as well as other
broader health systems issues influencing timely access to
healthcare are all likely to be relevant to outcomes.
We set out to understand the factors associated with outcome
for patients with CM in a public sector hospital setting within
northern KwaZulu-Natal, South Africa, where the prevalence of
HIV infection reaches 20% or more among the general adult
population.
Methods
This study was carried out at Ngwelezane hospital, a 550 bed
regional government hospital in Northern KwaZulu-Natal, South
Africa. KwaZulu-Natal is the South African province worst affected
by HIV with an estimated 1.5 million infected individuals [7]. The
hospitaloffers both districtand regional services. 440,000 peoplefall
under the hospital’s district catchment area, only patients from this
area were included in the study as for patients referred from other
hospitals it was not possible to get baseline information.
All patients diagnosed with cerebrospinal fluid (CSF) culture
positive CM during 2007 were included in the study. Verbal
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collection of relevant data from the patient’s chart.
The decision to initiate CM treatment was based on a clinical
diagnosis supported by positive Indian Ink microscopy. Patients
were treated according to local hospital protocol with amphotericin
B (AmB) 0.7 mg/kg daily for 14 days when supplies were available.
Liposomal formulations were not available. 1 litre of normal saline
was given before each dose of AmB, further intravenous fluids were
given at the discretionof the treating doctor. Wherepossible lumbar
puncture was repeated on days 7 and 14. Additional lumbar
punctures were carried out if the patient developed severe headache
believed by the clinician to be due to CM. CSF pressure
measurement was not routinely performed as appropriate equip-
ment was usually not available. Patients who had renal impairment
on admission (define as serum creatinine .220 umol/l) were
treated with fluconazole 400 mg daily rather than AmB in line with
South African treatment guidelines at the time of the study. If a
patient’s renal function improved following hydration, AmB was
started at standard dosage.
All patients had full blood counts, electrolytes (U&E) and liver
function tests performed prior to initiating therapy with AmB.
U&E was repeated every 48 hours. Electrolyte abnormalities were
corrected where possible. Where possible, cannulation sites were
rotated every 72 hours to prevent thrombophlebitis. Patients
developing renal impairment were given increased intravenous
fluids. If a patient’s creatinine rose to .220 umol/l AmB was
stopped and fluconazole 400 mg daily started. If the patients renal
function improved AmB was restarted. If the patient’s renal
function deteriorated again AmB was terminated for good and
substituted with fluconazole 400 mg daily. Flucytosine was not
available during the study period.
As a regional centre, the hospital has both CT and MRI scans
available. There is an on-site intensive care unit (ICU), but
medical patients are not routinely admitted to the unit and none of
the patients in this study were admitted to ICU. HAART has been
available locally through public sector provision since 2004. All
patients of unknown HIV status were offered VCT when clinically
well enough to consent, no patients were tested anonymously or
without consent. All patients not on HAART were offered
treatment under South African guidelines that take any WHO
stage IV illness (in this case CM) as an eligibility criterion for
initiating HAART. HAART was started only after 14 days of
AmB treatment, either as an inpatient, at a chronic care facility, or
most usually, at an outpatient ART clinic following discharge.
Data were collected by a physician (MD) using a standardized
data collection form. All patients were reviewed by the clinical
team daily, and study data was updated every 48 hours. Data were
entered into an excel spread sheet and verified on a separate
occasion. For survival analysis, patients were right censored at
date of discharge or date of later follow-up visit, with the outcome
being mortality. Person time was calculated as days from date
presenting at the hospital, as opposed to onset of disease, to date of
death or date of discharge or review for those still alive. Kaplan-
Meier analysis was used to determine the overall time to death and
mortality rate as well as 14 and 28 day mortality rates. Cox
regression analysis with Breslow method for ties was used to assess
variables that were independently associated with 14 day and 28
days mortality. STATA 10 (College Station, Texas, USA) was
used for analysis.
Results
Overall 92/186 (49.5%) individuals were male with a median
age of 33.5 years (IQR 28–39.5). The median age for women
was 30.5 years (IQR 27–36), significantly lower than for men
(P=0.019). Baseline characteristics are shown in Table 1.
148/186 (79.6%) individuals received amphotericin B, 28/186
Fluconazole (15.1%) and one patient both treatments. In 25/28
(89.3%) patients receiving initial treatment with fluconazole, the
treatment decision was based on the presence of renal failure. In
16 cases initially treated with amphotericin, patients were changed
to fluconazole because of the development of renal failure. Other
adverse events were uncommon, the most frequent side effect
being hypokalaemia that developed in 7/186 (3.8%) Individuals.
Overall mortality rate was 2.13 deaths per 100 person days
(95% CI 1.66–2.72). Mortality rates were higher in the first 14
days (2.54 per 100 person days, 95% C.I. 1.94–3.33) than the
second 14 days (2.12 per 100 person years 95% C.I. 1.65–2.73).
52/186 (28.0%) patients died as in-patients within the first 14 days
and 60/186 (32.3%) by 28 days (see Table 2). Data for overall
outcomes are shown in Table 2.
Survival Analysis
Kaplan Meier plots are shown in figure 1. Risks factors for 14
day and 28 day mortality are shown in Table 3. The final model
had 175 patients for 14 day mortality and 171 for 28 day
mortality. For 14 day mortality, 11 individuals had data missing
with respect to diastolic blood pressure. The presence of focal
neurological abnormality, diastolic hypotension, concurrent treat-
ment for TB and the use of fluconazole rather than amphotericin,
were associated with increased mortality at 14 and 28 days
(Table 3).
Discussion
Cryptococcal disease remains an important cause of mortality
particularly in sub-Saharan Africa, despite the increasing avail-
ability of antiretrovirals. We describe a prospective series of
individuals within a single health care setting operating within the
public health sector of South Africa. The strengths of this data are
that it is a large series, representative of outcomes in routine
practice within South Africa.
A high proportion of the mortality observed in this unselected
prospective case series was seen in the first 14 days. Unsurpris-
ingly, the mortality rates observed are substantially higher than
those in a western setting where mortality of 2.5–15% is more
typical [8,9] and have improved since the advent of HAART[10].
A significant number of individuals left hospital prior to
completion of CM treatment and thus the true mortality might
be higher than observed, though even if it were pessimistically
assumed that all patients discharged alive died within the first 14
days after starting treatment, mortality rate would rise to only
31%. By comparison to a recent study from a centre in central
Kampala, Uganda [11] mortality rates observed here were higher
than seen in the post-HAART era raising important questions as
to what factors are predictive of a poor outcome to treatment,
though such differences could be explained by exclusion of
comatose patients and those on fluconazole in that study.
The association of focal neurology with poorer outcome is
perhaps not surprising, suggesting as it does the presence of more
severe disease. The association between diastolic hypotension and
increased mortality has not been described previously. High blood
pressure can reflect raised intracranial pressure and might be
expected to be associated with a poorer outcome. However, in this
study, headache (also a feature of raised intracranial pressure) was
associated with better outcome. Diastolic hypotension might
reflect other concurrent infections (for example, bacterial infection)
or metabolic disturbance (for example, hypoadrenalism) that may
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losis treatment has not been described previously and is potentially
specific to this population with very high rates of TB transmission.
Assuming good adherence to medication, it is unlikely that these
patients had active TB meningitis at the time of admission,
although a small number of patients might have multi-drug
resistant disease. Rifampicin can potentially reduce therapeutic
levels of fluconazole but the effect on mortality was independent of
treatment choice and most patients received amphotericin. Given
the high burden of tuberculosis in local practice and limited
diagnostics, there is a low threshold for initiation of empiric TB
treatment in local practice and that it is possible that in some
patients this delays the diagnosis of other conditions, including
cryptococcal meningitis.
As results in table 3 demonstrate, there is clear evidence here for
a poorer outcome in patients receiving fluconazole monotherapy
rather than amphotericin. The majority of patients receiving
fluconazole had co-existing renal failure which precluded the use
of amphotericin (with liposomal formulations not available) and it
is thus possible that the fluconazole-treated group over-represents
individuals with severe disease. Given the co-linearity of The
variables for choice of treatment and renal failure, it is not possible
to separate these effects in analysis here, but a model including
Table 1. Description of 186 patients diagnosed with
Cryptococcal meningitis, presenting at Ngwelezana hospital.
Variable n n for group %
sex 186 Male 92 49.5
female 94 50.5
Over all male female
age 186 Mean 33.8 34.6 33.04
Median 32 33.5 30.5
IQR 27–38 28–39.5 27–36
n for group %
Case type 186 New 154 82.8
Retreatment 32 17.2
Headache 186 No 29 15.6
yes 157 84.4
Fever 186 No 153 82.3
yes 33 17.7
Fits 186 no 171 91.9
yes 15 8.1
Confusion 186 No 144 77.4
yes 42 22.6
Vomiting 186 No 101 54.3
yes 85 45.7
Neck pain 186 No 43 23.1
yes 143 76.9
Zoster 186 no 181 97.3
yes 5 2.7
Focal Neurology 186 no 181 97.3
Yes 5 2.7
CD4 cells/ul 119 Mean 90.8
Median 46
IQR 17–100
Systolic BP 175 Mean 115
Median 113
IQR 101–125
,100 39 22.3
Normal (100–140) 114 65.1
.140 22 12.6
Diastolic BP 175 Mean 74.1
Median 72
IQR 63–87
,60 30 17.1
Normal (60–90) 113 64.6
.90 32 18.3
Glasgow Coma Normal (15) 147 86
Score Abnormal (,15) 24 14
Tuberculosis Never 84 45.2
past 47 25.3
Current 38 20.4
Past and current 17 9.14
HIV status 186 Positive on admission 112 60.2
Positive in hospital 26 14
Variable n n for group %
unknown 48 25.8
On ART 186 No 159 85.5
yes 27 14.5
Illness duration 174 Mean 13.1
Median 7
IQR Apr-14
Treatment given 186 Amphotericin 148 79.6
Fluconazole 28 15.1
Both 1 0.5
none 9 4.8
Reason 164 None 139 84.8
Renal failure 25 15.2
*P for differences in median age by sex=0.019.
doi:10.1371/journal.pone.0008630.t001
Table 1. Cont.
Table 2. Period mortality rates in a cohort of 186 patients
admitted in hospital due to cryptococcal meningitis.
Time N %
Exposure
time in days
Mortality rate per
100 person days 95% C.I
Overall Alive 123 66.13
Dead 63 33.87 2963 2.13 1.66–
2.72
14 days Alive 134 72.04
Dead 52 27.96 2047 2.54 1.94–
3.33
28 days Alive 126 67.74
Dead 60 32.26 2829 2.12 1.65–
2.73
doi:10.1371/journal.pone.0008630.t002
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better fit to the data seen
Given the known superiority of AmB over fluconazole, a study
of AmB in patients with renal failure could be justified from these
data in resource-limited setting. In addition, studies using higher
doses of fluconzaole will be helpful to improve the evidence base
for non amphotericin based regimens[12]. Non-governmental
guidelines issued during this study [13] recommend fluconazole at
a higher dose of 800 mg/day and might offer additional benefit.
Whether the addition of flucytosine to existing regimens would
substantially impact mortality is unknown and the drug remains
expensive. There is good evidence that the addition of flucytosine
to AmB treatment is more rapidly fungicidal than AmB alone [14]
though in a large RCT in a western setting [9] of 408 patients, no
difference in mortality could be seen at two weeks. However, it
remains possible that improved drug treatment could have more
impact in a setting with higher background mortality where the
relative impact of drug choice on mortality might be higher.
Recent work the relationship between rate of fungal CSF
clearance over the first 14 days of treatment and clinical outcome
suggests a method by which different treatment combinations
could be tested [15].
Perhaps surprisingly, there was no positive effect on outcome for
patients established on HAART prior to diagnosis of CM.
However, the duration of follow-up was probably not long enough
to see the benefits of HAART seen elsewhere [16]. However, other
data has suggested a potential benefit for HAART as early as two
weeks [17,18]. One of the limitations of this study was that it was
not designed to study immune reconstitution inflammatory
syndrome (IRIS). A proportion of those already on antiretrovirals
might have experienced ‘‘unmasking IRIS’’ presenting early into
treatment but data was not collected on duration of antiretroviral
treatment to help understand this more. IRIS is undoubtedly a
challenge for patients starting ART in the setting of CM [19].
Whilst ACTG 5164 [20], a strategic management trial largely
recruiting in US centers with only a small number of CM patients,
found no risk to early ART initiation, recent data from a larger
study suggests a potential benefit to delaying the initiation of
HAART in patients with CM [21]. However, early initiation of
HAART following the diagnosis of CM was not common in this
cohort and unlikely to have had a significant effect on mortality.
Figure 1. Kaplan-Meier time to death following diagnosis of
cryptococcal meningitis andsubsequent admissioninto hospital.
doi:10.1371/journal.pone.0008630.g001
Table 3. Risk factors for in-hospital mortality within 14 days and 28 days in patients diagnosed with cryptococcal meningitis.
Variable 14 day mortality 95% C.I. P 28 day mortality 95% C.I. P
Sex Female 0.63 0.32–1.27 0.2 0.95 0.52–1.73 0.862
Age 0.99 0.96–1.03 0.72 0.99 0.97–1.03 0.843
Headache No 1 N/S
Yes 0.58 0.28–1.19 0.137
Focal neurology No 1 1
Yes 11 3.08–39.28 ,0.001 8.14 2.58–25.7 ,0.001
CD4 .50 1 1
,50 0.7 0.29–1.66 0.413 1.02 0.48–2.20 0.951
Missing 1.49 0.68–3.26 0.322 2.06 1.00–4.31 0.05
Diastolic BP Normal 1 1
,60 2.37 1.11–5.04 0.025 2.34 1.18–4.63 0.015
.90 1.64 0.68–3.99 0.272 1.1 0.49–2.44 0.824
Missing 0.86 0.21–3.52 0.837 0.61 0.17–2.21 0.454
GCS Normal (15) 1 N/S
Abnormal (,15) 2.05 0.91–4.59 0.081
Missing 1.57 0.64–3.83 0.323
TB Never 1 1
Past 1.83 0.79–4.23 0.158 1.88 0.88–4.01 0.101
Current 2.11 1.02–4.35 0.044 2.2 1.13–4.30 0.02
Past and current 0.92 0.26–3.29 0.903 0.62 0.18–2.11 0.445
Treatment Amphotericin 1 1
Fluconazole 3.69 1.74–7.85 0.001 5.16 2.71–9.83 ,0.001
doi:10.1371/journal.pone.0008630.t003
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the South African public sector. The facilities available lie between
the extremes seen in developed countries and those in poorer (non-
specialist) centres in sub-Saharan Africa. Drug treatment is
available, with AmB the preferred first line option. Patients are
usually managed by trained physicians but healthcare workers at
all levels are in limited supply, drug and other medical supplies are
inconsistent and supportive facilities (HDU,ICU), whilst theoret-
ically available, are not routinely used for medically unwell
patients. In well-resourced environments, it has become increas-
ingly clear that the outcome for patients on ICU is not greatly
different for those with HIV when compared to those without
[22]. Data from this study can start to make an evidence based
case for selecting those individuals who would benefit from more
intensive support when it is available.
Detailed prevalence data from the nearby region [23] and
experience of local antiretroviral programmes, suggests that the
structure of the local population and relative prevalence of HIV
between men and women, means more women both have HIV
and access treatment. The similar proportions of men and women
in this study therefore suggests that men within the local
population are more likely than women to access care late and
with WHO stage IV illness compared to what would be predicted.
This cannot be fully substantiated with data from the wider
immediate population, but is consistent with local experience. Late
presentation is a key factor in improving outcome. With HAART
widely available in many setting such as our own, all these deaths,
and even disease presentations could be avoidable. The median
duration of symptoms prior to presentation was 13 days in this
study, very similar to that observed in Uganda [11]. Interventions
that target earlier diagnosis and access to care are crucial if
mortality is to be improved. In this regard, discussions within
South Africa and elsewhere towards increasing the threshold at
which individuals become eligible for antiretrovirals (in line with
WHO recommendations) should be welcomed. In parallel to such
efforts, studies looking to improve available treatments in resource
poor settings should continue to be a priority.
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